Lovastatin

Generic Name: Lovastatin

Brand Names: Advicor, Altoprev

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₆O_₅

CAS Number: 75330-75-5

Unique Ingredient Identifier: 9LHU78OQFD

Background: Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of Aspergillus terreus. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inh...

Indication: Lovastatin is indicated to reduce the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C. It is indicated as an intervention alternative in individuals presenting dyslipidemia...

Associated Conditions: Apolipoprotein, Cholesterol, LDL, Coronary Artery Atherosclerosis, Coronary Revascularization, Myocardial Infarction, Peripheral Arterial Disease (PAD), Unstable Angina Pectoris, Elevation of serum triglyceride levels, Total cholesterol increased

Associated Therapies: -

Clinical Trials

Pharmacological Treatment of Rett Syndrome With Statins

Phase 2

Completed

Conditions: Rett Syndrome

Interventions: Drug: Lovastatin

First Posted Date: 2015-09-30

Last Posted Date: 2019-07-12

Lead Sponsor: Montefiore Medical Center

Target Recruit Count: 20

Registration Number: NCT02563860

Locations: 🇺🇸
Montefiore Medical center, Bronx, New York, United States

High Potency Statins and Acute Kidney Injury

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Rosuvastatin (≥10 mg)
Drug: Fluvastatin
Drug: Atorvastatin (≥20 mg)
Drug: Pravastatin
Drug: Simvastatin (≥40 mg)
Drug: Lovastatin
Drug: Atorvastatin (<20mg)
Drug: Simvastatin (<40 mg)

First Posted Date: 2015-08-07

Last Posted Date: 2016-03-14

Lead Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES

Target Recruit Count: 2067639

Registration Number: NCT02518516

Locations: 🇨🇦
Dept. of Anesthesiology, Pharmacology & Therapeutics (APT), University of British Columbia, Vancouver, British Columbia, Canada

High Potency Statins and the Risk of Diabetes

Completed

Conditions: Diabetes Mellitus, Type 2
Cardiovascular Disease

Interventions: Drug: Rosuvastatin (≥10 mg)
Drug: Fluvastatin
Drug: Atorvastatin (≥20 mg)
Drug: Pravastatin
Drug: Simvastatin (≥40 mg)
Drug: Lovastatin
Drug: Rosuvastatin (<10mg)
Drug: Atorvastatin (<20mg)
Drug: Simvastatin (<40 mg)

First Posted Date: 2015-08-07

Last Posted Date: 2016-03-14

Lead Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES

Target Recruit Count: 136966

Registration Number: NCT02518503

Effects of Lovastatin on Human Platelet Proteome

Phase 2

Completed

Conditions: Blood Platelets Proteome

Interventions: Drug: Lovastatin

First Posted Date: 2015-03-17

Last Posted Date: 2015-06-16

Lead Sponsor: Université de Sherbrooke

Target Recruit Count: 15

Registration Number: NCT02389868

Locations: 🇨🇦
Centre de Recherche du CHUS, Sherbrooke, Quebec, Canada

Pre-Prostatectomy Lovastatin on Prostate Cancer

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Lovastatin

First Posted Date: 2011-11-23

Last Posted Date: 2019-03-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 2

Registration Number: NCT01478828

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Human Cytochrome P450 4F Enzymes and Drug Interactions

Phase 1

Completed

Conditions: Healthy Volunteers
Drug Drug Interactions

Interventions: Drug: Warfarin
Drug: Lovastatin
Drug: Placebo

First Posted Date: 2010-11-30

Last Posted Date: 2013-01-21

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 19

Registration Number: NCT01250535

Locations: 🇺🇸
University of North Carolina, Clinical and Translational Research Center (CTRC), Chapel Hill, North Carolina, United States

Novel Treatment for Syndromic Ichthyoses

Phase 2

Withdrawn

Conditions: Smith Lemli Opitz Syndrome
Conradi Syndrome
Syndromic Ichthyoses
CHILD Syndrome

Interventions: Drug: Lovastatin

First Posted Date: 2010-04-26

Last Posted Date: 2015-05-19

Lead Sponsor: Northwestern University

Registration Number: NCT01110642

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

Phase 2

Withdrawn

Conditions: Melanoma
Malignant Melanoma

Interventions: Drug: lovastatin
Drug: interferon alfa-2b

First Posted Date: 2009-08-21

Last Posted Date: 2009-09-09

Lead Sponsor: NeoPlas Innovation

Target Recruit Count: 250

Registration Number: NCT00963664

Locations: 🇺🇸
NeoPlas Innovation, Nashville, Tennessee, United States

Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer
Radiation Toxicity

Interventions: Drug: lovastatin
Other: questionnaire administration
Procedure: adjuvant therapy
Radiation: accelerated partial breast irradiation
Radiation: external beam radiation therapy

First Posted Date: 2009-05-15

Last Posted Date: 2013-06-20

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 3

Registration Number: NCT00902668

Lovastatin: Immunomodulatory Value Evaluation

Phase 2

Completed

Conditions: HIV Seropositivity

Interventions: Other: placebo
Drug: Lovastatin

First Posted Date: 2008-07-24

Last Posted Date: 2011-10-04

Lead Sponsor: Universidad de Antioquia

Target Recruit Count: 112

Registration Number: NCT00721305

Locations: 🇨🇴
Group of Immunovirology, Research Universitary Center, University of Antioquia, Medellin, Antioquia, Colombia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy